Myostain is involved in ginsenoside Rb1-mediated anti-obesity

Area of Science:

• Metabolic research
• Pharmacology
• Obesity research

Background:

• Obesity is a significant global health concern.
• Ginsenoside Rb1, from Panax ginseng, shows potential benefits for obesity and diabetes.
• The precise mechanisms of Rb1 in obesity regulation require further investigation.

Purpose of the Study:

• To elucidate the mechanism by which Ginsenoside Rb1 regulates obesity.
• To investigate the role of the myostatin (MSTN)/fibronectin type III domain-containing 5 (FNDC5) pathway in Rb1's anti-obesity effects.

Main Methods:

• Obese C57BL/6 mice were treated with Ginsenoside Rb1 (40 mg/kg/d) or saline for four weeks.
• In vitro studies involved treating C2C12 and 3T3-L1 cells with varying concentrations of Rb1.
• Expression of MSTN and FNDC5 was analyzed in cells and adipose tissues.

Main Results:

• Rb1 treatment led to reduced body weight, smaller adipocyte size, improved glucose tolerance, and increased metabolic activity in mice.
• MSTN expression was downregulated, while FNDC5 expression was upregulated by Rb1 in vitro and in vivo.
• Overexpression of MSTN counteracted the lipid droplet reduction in 3T3-L1 adipocytes induced by Rb1.

Conclusions:

• Ginsenoside Rb1 ameliorates obesity, potentially via the MSTN/FNDC5 signaling pathway.
• Rb1 demonstrates potential as an effective therapeutic agent for human obesity.